Trial Profile
First line Therapy by Sorafenib for Lung Metastases Patients in Renal Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Cancer metastases; Renal cell carcinoma
- Focus Therapeutic Use
- 15 Sep 2015 Status changed from recruiting to active, no longer recruiting, according to University Hospital Medical Information Network - Japan record.
- 23 Feb 2011 New trial record